- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Hologic cofounder dies
S. David Ellenbogen, Hologic’s chair and CEO, died unexpectedly June 21 from heart failure. A pioneer of bone densitometry, Ellenbogen cofounded Hologic and served as CEO and chair since its formation 16 years ago. In addition to corporate duties
S. David Ellenbogen, Hologic’s chair and CEO, died unexpectedly June 21 from heart failure. A pioneer of bone densitometry, Ellenbogen cofounded Hologic and served as CEO and chair since its formation 16 years ago. In addition to corporate duties at Hologic, Ellenbogen lobbied state and federal officials on behalf of small companies throughout the medical device industry. His professional efforts underscored the integrity and good will that friends and associates experienced firsthand. Jay A. Stein, executive vice president and CTO, has been appointed Hologic chair. Stein will serve as interim CEO, until the company’s board of directors fills the position permanently.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.
